pharma · Breast Cancer
Mylan IRE Healthcare Limited
MYLAN PHARMACEUTICALS PRIVATE drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
MYLAN PHARMACEUTICALS PRIVATE drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.